FGFR Inhibition in Advanced CCA

Infigratinib in previously treated advanced CCAПодробнее

FGFR InhibitorsПодробнее

Webinar: First-in Human-Studies of FGFR Inhibitor KIN-3248 and RAF Inhibitor KIN-2787Подробнее

FGFR2 Inhibitors in Advanced CholangiocarcinomaПодробнее

Dr. Roychowdhury on FGFR Inhibitor Infigratinib in CholangiocarcinomaПодробнее

Natural history of patients with advanced CCA with FGFR2 gene alterations or wild-type FGFR2Подробнее

FGFR Inhibitors in Development for CCAПодробнее

FGFR Inhibition in Advanced CCAПодробнее

2018 Cholangiocarcinoma Foundation Annual Conference #11 - Day 2 - FGFR InhibitionПодробнее

Expansion cohort results of RAGNAR: erdafitinib in CCA with FGFR alterationsПодробнее

Webinar: TT-00420 TreatmentПодробнее

FGFR Inhibitor Clinical TrialsПодробнее

FGFR Inhibitor Toxicity ProfileПодробнее

Webinar: Targeting the FGFR pathway: Infigratinib in cholangiocarcinomaПодробнее

The Future of FGFR Inhibitor TreatmentПодробнее

Day 3 - acquired resistance to FGFR inhibitorsПодробнее

FGFR Inhibitor MOA and Adverse EventsПодробнее

Advances in FGFR inhibition for hepatobiliary cancerПодробнее

FGFR Inhibitors for CCA & Bladder CancerПодробнее

FGFR MutationsПодробнее

Infigratinib for CCAПодробнее